Lupin bags tentative USFDA nod for Loteprednol Etabonate Ophthalmic Gel

Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax SM) had an estimated annual sale of USD 36 million in the U.S. (IQVIA MAT November 2024).

Read also: Safety of Lupin's Ranibizumab (Ranieyes) established in Large-Scale Multicenter Study with 2194 injections in 1401 eyes

Medical Dialogues team had earlier reported that the company had received approval from the U.S. FDA for its Abbreviated New Drug Application for Brimonidine Tartrate Ophthalmic Solution, 0.1%. Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Read also: Lupin bags tentative USFDA okay for Abacavir, Dolutegravir, Lamivudine Tablets for Oral Suspension for HIV treatment

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a workforce of over 22,000 professionals.

Read also: Lupin Digital Health collaborate with Medicover Hospitals for post-discharge cardiac care